<DOC>
	<DOCNO>NCT00398307</DOCNO>
	<brief_summary>This Phase I , open-label study evaluate PK S-1 component metabolites patient advance solid tumor vary degree renal function . Patients stratified baseline 24-hour creatinine clearance ( CrCL ) 4 cohort use normal clearance formula : Group A : Control Group B : Mild renal dysfunction Group C : Moderate renal function Group D : Severe renal dysfunction . Six patient enrolled cohort .</brief_summary>
	<brief_title>Evaluating Patients With Varying Degrees Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>A patient must meet follow inclusion criterion eligible enrollment study : 1 . Has histologically cytologically proven advanced solid tumor standard therapy exists . 2 . Has provide write informed consent . 3 . Is 18 year age old . 4 . Is able take medication orally . 5 . Has Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 ≤ 2 Appendix A , ECOG Performance Status ) . 6 . Has adequate organ function define follow criterion : 1 . Transaminases AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 time upper limit normal ( ULN ) . If liver function abnormality due underlying malignancy , AST ( SGOT ) ALT ( SGPT ) may ≤ 5 time ULN . 2 . Total serum bilirubin ≤ 1.5 time ULN . 3 . Absolute granulocyte count ≥ 1,500/mm3 ( ie , ≥ 1.5 x 109/L International Units [ IU ] ) . 4 . Has platelet count ≥ 100,000/mm3 ( IU : ≥ 100 x 109/L ) . 5 . Has hemoglobin value ≥ 9.0 g/dL . 7 . Is willing able comply schedule visit , treatment plan , laboratory test , study procedure . 3.3.2 Exclusion Criteria Exclude patient study he/she fulfill inclusion criterion , follow condition observe : 1 . Has treatment follow within specified time frame prior study drug administration : 1 . Any investigational agent receive either concurrently within last 30 day . 2 . Previous therapy malignancy within 21 day , include chemotherapy , immunotherapy , biologic hormonal therapy ( 6 week nitrosoureas mitomycin ( C ) . 3 . Previous radiotherapy within 14 day . 4 . Current enrollment another clinical trial . 2 . Has serious illness medical condition ( ) include , limited , follow : 1 . Myocardial infarction within last 6 month , severe/unstable angina , congestive heart failure ( New York Heart Association [ NYHA ] Class III IV , Appendix E , NYHA Classification ) . 2 . Known ( time entry ) gastrointestinal disorder , include malabsorption , chronic nausea , vomit , diarrhea present extent might interfere oral intake absorption study medication . 3 . Known brain metastasis . 4 . Known leptomeningeal metastasis . 5 . Requires hemodialysis . 6 . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness . 7 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment Investigator would make patient inappropriate entry study . 3 . Is receive concomitant treatment drug interact S1 . The following drug prohibit may interaction S1 : 1 . Sorivudine , uracil , dipyridamole , cimetidine folinic acid ( may enhance S1 activity ) . 2 . Allopurinol ( may diminish S1 activity ) . 3 . Phenytoin ( S1 may enhance phenytoin activity ) . 4 . Flucytosine , fluorinated pyrimidine antifungal agent ( may enhance S1 flucytosine activity ) . 5 . Pilocarpine ( may inhibit CYP2A6 activity ) . 4 . Has know sensitivity 5FU . 5 . Is pregnant lactate female . 6 . Is patient reproductive potential refuse use adequate mean contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Renal Impairment</keyword>
</DOC>